Huge congratulations to Dr Muhammad Ali - winner of the Elekta Award at #RANZCR2025 for advances in the use of technology in #radiotherapy 🏆 Awarded for his Phase 2 RCT of Neoadj Pembro + #SABR before nephrectomy for #RCC (NAPSTER) @dr_alimuhammad @RANZCRcollege @PeterMacCC

Should we think about 3 tier SABR response following kidney SABR? @_ShankarSiva @ChadTangMD @jryckman3 @NicholasZaorsky I am just liking this initial version which I just put together for a recent talk. May be adding “reassuring” for non-progressive

5 weeks left to register for @PeterMacCC #SABR2025!   Expert discussions, interactive sessions, fantastic faculty @PeterMacRadOnc @PBlanchardMD @lauren_henke @BarbaraJereczek @DrewMoghanaki @Melissa_O_Neil This always sells out, register soon! https://t.co/O3ooI3ddky

Renal cell carcinoma squad at ASTRO 2025!

🆕 @dr_alimuhammad NAPSTER trial (n=20): First-in-human neoadjuvant SABR ± pembrolizumab before nephrectomy in ccRCC ✅ All pts completed SABR ± IO; 18/20 underwent nephrectomy (all R0) 🩺 no grade 4–5 AEs; surgical complications minimal ⭐️Feasible & safe; immune analyses to

On way to @ASTRO_org #ASTRO25. If you are attending, please join us on Monday 29/9 for session “Revelations in Renal radiotherapy” @_ShankarSiva @ChadTangMD

Median follow-up ccRCC group 4.02 and 4.29 years for nccRCC group •local recurrence @5y: 1.5% in ccRCC group vs. 2.4% in nccRCC group (hazard ratio [HR]: 0.90, 95% CI: 0.10-8.31, p=0.922) •distant failure @5y: 6.0% in ccRCC group vs. 2.9% in nccRCC group (HR: 0.34, 95% CI:

https://t.co/zNSBD5YVvV A recent analysis from IROCK in press. This time looking at outcomes for clear vs non-clear cell RCCs @_ShankarSiva @PeterMacRadOnc @DrCorreaRO @NicholasZaorsky

Few changes 1: dose, as suggested by @_ShankarSiva alternative dose schedule >40 Gy in 5 fractions 2: Premed (our routine practice) added in delivery section

Emerging PET tracers in RCC -—CA-IX, PSMA & sestamibi — high sensitivity/specificity for renal mass characterization & staging. Is this what the future holds in #kidneycancer ? Out now Weindler at al. @BMJ_Open https://t.co/n0LAU7ev5D #kcsm

Really excited to see this paper live on BMJ Oncology! The authors have provided a comprehensive overview of novel radiopharmaceuticals for molecular imaging of renal cell carcinoma🔬 https://t.co/svzoulrbL5 @_ShankarSiva @BMJOncology #oncology #renalcellcarcinoma

While working on a presentation, I come up with summary slide for a Kidney SABR. This is based on our experience mastered by @_ShankarSiva over the last 12 years. Good guide for the upcoming Ros in training.

Please join our esteemed international RO speakers in Melbourne in October for #RANZCR2025! Early bird registrations close 15 July 2025. https://t.co/LDUzn6gU2Q @RANZCRcollege @NiuSanford @reshmajagsi @SahgalArjun @AmarUKishan @SimonLo21054188 @jmmrad @BoekeSimon @GkikaEleni2

N 90 patients with primary renal cell carcinoma -Tumour Complexity: Most patients had moderately complex renal tumours (median R.E.N.A.L. nephrometry score of 9) with a median tumour size of 4.6 cm. Renal Function: The estimated glomerular filtration rate (eGFR) declined by

Our article to look at the impact of tumour complexity on outcomes following SABR for primary kidney cancer @_ShankarSiva @declangmurphy @PeterMacRadOnc @PeterMacCC https://t.co/ho9dSqUrk5

Today, we achieved a small milestone of registering the 100th prospective patient at Peter MacCallum Cancer Centre. @_ShankarSiva @MellyB_7 @declangmurphy @PeterMacRadOnc @PeterMacCC https://t.co/wMmof6KQXA

Right atrial angiosarcoma not for surgery 5.5cm What should be the radiotherapy dose/fraction? @DrewMoghanaki @jryckman3 @_ShankarSiva

Is there a role for PSMA PET/CT in oligometatastic RCC? Check out our @JournalofNucMed PEDESTAL study on PSMA-guided metastasis-directed therapy from @PeterMacCC @_ShankarSiva @DrMHofman 🧍33 pts & 60 metastases 🛜 93% radiotherapy 📖Median follow-up> 4y ✅Local control: 94%

MRI awaited